Table 4. Multivariate analysis of the associations between significant prognostic factors and survival outcomes in the propensity-matched cohort.
| Outcome | Hazard ratio | 95% CI | P-value |
|---|---|---|---|
| Overall survival | |||
| Sex female vs. male | 0.73 | 0.50-1.06 | 0.098 |
| Age > 45 vs. ≤ 45 years | 1.47 | 1.10-1.97 | 0.009 |
| T category T1-2 vs.T3-4 | 1.50 | 1.23-1.82 | 0.000 |
| N category N0-1 vs. N2-3 | 1.72 | 1.43-2.08 | 0.000 |
| Treatment arm IC/CCRT vs. IC/RT | 0.87 | 0.65-1.16 | 0.331 |
| Distant-free survival | |||
| Sex female vs. male | 0.70 | 0.48-1.00 | 0.051 |
| Age > 45 vs. ≤ 45 years | 1.30 | 0.99-1.71 | 0.064 |
| T category T1-2 vs.T3-4 | 1.38 | 1.14-1.67 | 0.001 |
| N category N0-1 vs. N2-3 | 1.62 | 1.36-1.93 | 0.000 |
| Treatment arm IC/CCRT vs. IC/RT | 0.93 | 0.71-1.22 | 0.597 |
| Distant metastasis-free survival | |||
| Sex female vs. male | 0.60 | 0.34-1.06 | 0.080 |
| Age > 45 vs. ≤ 45 years | 1.38 | 0.92-2.08 | 0.119 |
| T category T1-2 vs.T3-4 | 1.51 | 1.14-2.00 | 0.004 |
| N category N0-1 vs. N2-3 | 1.82 | 1.40-2.38 | 0.000 |
| Treatment arm IC/CCRT vs. IC/RT | 0.92 | 0.62-1.38 | 0.688 |
| Locoregional relapse-free survival | |||
| Sex female vs. male | 0.74 | 0.39-1.43 | 0.373 |
| Age > 45 vs. ≤ 45 years | 0.93 | 0.56-1.54 | 0.785 |
| T category T1-2 vs.T3-4 | 0.86 | 0.61-1.22 | 0.398 |
| N category N0-1 vs. N2-3 | 1.25 | 0.89-1.75 | 0.193 |
| Treatment arm IC/CCRT vs. IC/RT | 1.36 | 0.82-2,27 | 0.238 |
IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; RT: radiotherapy; CI, confidence interval.